clinical trial – Page 192 – Communicable Diseases Research

International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019

Clinical Investigations

Published on 2020-11-182022-11-01
Journal: Critical Care Medicine [Category] COVID-19, SARS,

[키워드] analyzed Anxiety Blood cardiovascular disease chest pain Chinese clinical trial Clinicians conducted content coronavirus coronavirus disease country Critical Critical care Digital English fatigue gastrointestinal problems generate groups Health highest Infection Italian knowledge life-threatening Likert scale lung median Mortality organ Organ failure outcome outcomes oxygen Pain participant patients Pneumonia professional professionals researchers Respiratory failure scale scarring Sepsis Shortness of breath Spanish survey their family members three group tolerable Trial trials Variability
[DOI] 10.1097/CCM.0000000000004584 PMC 바로가기 [Article Type] Clinical Investigations

COVID-19 pandemic crisis—a complete outline of SARS-CoV-2

Review

Published on 2020-11-172022-10-31
Journal: Future Journal of Pharmaceutical Sciences [Category] COVID-19,

Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives

Molecular Biosciences

Published on 2020-11-172022-10-31
Journal: Frontiers in Molecular Biosciences [Category] COVID-19,

Core Outcomes Set for Trials in People With Coronavirus Disease 2019

Clinical Investigations

Published on 2020-11-172022-11-01
Journal: Critical Care Medicine [Category] COVID-19, SARS,

A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs

Pharmacology

Published on 2020-11-172022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] acute respiratory syndrome alleviate anti-viral agents antiviral agent Antiviral effect Asymptomatic benefit blunt children China Chinese Chloroquine clinical clinical evidence clinical trial convalescent plasma coronavirus disease Coronavirus-2 COVID-19 COVID-19 patient Critical critical COVID-19 patient cytokine release Cytokine release syndrome drug early stage Efficacy Favipiravir highlight Hydroxychloroquine in vitro Inflammation inhibit inhibitor initial interferon interleukin-6 interleukin-6 inhibitors late stage Mild MOST Negative conversion non-randomized observational study pandemic Patient patients with COVID-19 Pediatric case Prophylaxis repurposing review ribavirin sample-size SARS-CoV-2 severe COVID-19 patient severe patients small sample size Study design therapeutic option therapy Traditional Chinese medicine Treatment treatment initiation with mild disease
[DOI] 10.3389/fphar.2020.584956 PMC 바로가기 [Article Type] Pharmacology

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease

Chemistry

Published on 2020-11-162022-10-31
Journal: Frontiers in Chemistry [Category] COVID-19,

[키워드] absence activity acute respiratory syndrome analyzed Antiviral approved candidate Candidates ChEMBL clinical trial complex coronavirus coronavirus disease costly COVID-19 dataset docked docking scores downloaded drug Drug discovery Drug repurposing effective Health identify in silico in vitro inhibitor Interaction knowledge molecular docking molecular interaction fingerprints pandemic papain-like cysteine protease Papain-like protease Peptide inhibitor PLPro Polypharmacology released repurposing SARS-CoV-2 SARS–CoV–2 similarities Spread the SARS-CoV-2 therapeutic strategy time-consuming Treatment Vaccine Virtual screening
[DOI] 10.3389/fchem.2020.594009 PMC 바로가기 [Article Type] Chemistry

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Research

Published on 2020-11-142022-10-30
Journal: Immunity & Ageing : I & A [Category] COVID-19,

[키워드] agency Alpha approved baseline levels circulating clinical trial Concentration COVID-19 COVID-19 outbreak COVID-19 patient COVID-19 patients Cuba Cytokine release syndrome Cytokine storm decrease Disease progression dose elderly Elderly patient Healthcare system humanized IL-6 ill patient ill patients INF-γ interferon gamma itolizumab kinetic mechanism Mild moderate disease monoclonal antibody MOST multiple comorbidities multiple comorbidity Necrosis outcome Patient reduce reducing Registered Regulatory reported Result rheumatoid arthritis serum severe COVID-19 severe symptoms severely ill patients the cytokine storm therapeutic option TNFα treated
[DOI] 10.1186/s12979-020-00207-8 PMC 바로가기 [Article Type] Research

Vitamin D3 as Potential Treatment Adjuncts for COVID-19

Review

Published on 2020-11-142022-10-31
Journal: Nutrients [Category] COVID-19, SARS,

[키워드] “cytokine storm” Activation Acute respiratory infection acute respiratory syndrome Adaptive immune response adjunct ARDS cause characterized clinical trial coronavirus COVID-19 Critical distress drug dysregulation effort Health Host immune response IL-1 IL-6 immune activation immunomodulation immunomodulatory Infection Infectious disease inflammatory process Innate immunity mechanism Meta-analysis observational study pandemic Potential prevention promote Protective receptor risk SARS-CoV2 SARS-CoV2 immunopathology SARS-CoV2 infection significant increase supported syndrome systemic hyperinflammation therapy Vaccine VDR viral infection Vitamin D Vitamin D receptor Vitamin D supplementation Vitamin D3
[DOI] 10.3390/nu12113512 PMC 바로가기 [Article Type] Review

Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective

Neurology

Published on 2020-11-132022-11-01
Journal: Frontiers in Neurology [Category] COVID-19,

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking

COVID-19에 대한 용도 변경 치료제: 머신 러닝 및 도킹을 통해 상업적으로 이용 가능한 약물의 신속한 예측

Research Article

Published on 2020-11-122022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] accelerate Accuracy Amprenavir antiretroviral drug approach approved can be used caused clinical recovery clinical trial clinical trials Community coronavirus disease COVID-19 COVID-19 treatment criterion disease docking drug drug design Drug discovery DrugBank drugs effective Epidemic epidemic disease FDA futuristic smart drug designing strategy globe help improvement infected case machine learning market medication ML model mortality rate Naive Bayes algorithm new drug combination new virus Novel coronavirus novel coronavirus disease other disease other diseases outbreak predict protocol protocols Rapid reported repurposing required researcher SARS-CoV-2 SARS-CoV-2 virus selected selective Spread the disease the SARS-CoV-2 virus therapeutic agent therapeutic agents treat Treatment treatment of COVID-19 treatment regimen treatment regimens Vaccines virus
[DOI] 10.1371/journal.pone.0241543 PMC 바로가기 [Article Type] Research Article